Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock
Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system,
including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.
- Sichenzia Ross Ference LLP Represents High Tide Inc. in the $20.64 million acquisition of Fab Nutrition, LLC - May 11, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital in $48.3 Million Underwritten Public Offering of Farmmi, Inc. - May 3, 2021
- Sichenzia Ross Ference LLP Wins Appeal Before the Second Circuit in a Lawsuit Brought By Investors in Connection with a Private Placement - April 30, 2021